J&J Rybrevant Update Could Bode Positively For AstraZeneca’s Tagrisso

A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.

Question mark
Investors questioned the meaning behind a Rybrevant trial continuing to a final analysis • Source: Shutterstock

Johnson & Johnson’s ambition to position a combination regimen of the bispecific antibody Rybrevant (amivantamab) and EGFR inhibitor lazertinib as superior to AstraZeneca PLC’s Tagrisso (osimertinib) for certain types of non-small cell lung cancer (NSCLC) seems uncertain after the company said a Phase III clinical trial testing the two regimens head-to-head passed an interim analysis without stopping for efficacy or safety.

Management revealed during the company’s first quarter sales and earnings call on 18 April that the Phase III MARIPOSA trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

Pipeline Watch: Twelve Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.